Premium
Treatment and results of recurrent cancer of corpus uteri in patients receiving anterior and total pelvic exenteration. 1947–1963
Author(s) -
Barber Hugh R. K.,
Brunschwig Alexander
Publication year - 1968
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196811)22:5<949::aid-cncr2820220509>3.0.co;2-7
Subject(s) - pelvic exenteration , medicine , corpus uteri , surgery , cancer , endometrial cancer , disease , cervix
In cases of cancer corpus uteri in New York state, 30% of these patients have recurrent or persistent disease. The authors question whether further therapy, in the form of exenteration, should be offered to these patients. Of 36 patients receiving pelvic exenteration 5 or more years ago, seven received their initial treatment less than 1 year prior to treatment for recurrence and none survived more than 15 months. Of the 29 patients who were free of disease for at least 1 year after initial treatment and before receiving exenteration for recurrence, five lived 5 or more years. It is concluded that there is a limited place for pelvic exenteration in the treatment of recurrent endometrial cancer.